Savara Inc(SVRA)stock report

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.

Finance:
Market Cap:202.3M; Shares Outstanding:41.2M; Short Interest: 1.96%; Q3 2019(9/30/19): Cash 106M. Loss 12.4M

EPS and Sales:
https://finance.yahoo.com/quote/SVRA/financials?p=SVRA

Date EPS % last year % last quarter
2018.12.31 -1.85 -5.11% -17.83%
2019.3.31 -0.34 60.47% -81.62%
2019.6.30 -0.91 26.02% -167.65%
2019.9.30 -1.2 23.57% -31.87%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=SVRA&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/SVRA/institutional-ownership/

2019.12.31:
Total institutions: 93,no change
Shares hold: 15310.8k shares. no change
shares% hold: 37.15%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/SVRA/price-targe

Leave a Reply